TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Line Vibholm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.